Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2017-04-06 AGM Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 19 pages 693.7KB
AGM Information Classification · 95% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Statement' for Cyclopharm Limited, detailing the date, time, and location of the AGM, the agenda including financial statements, remuneration report, director elections, share buy-back, and remuneration increase for non-executive directors. It includes proxy voting instructions, voting entitlements, and explanatory notes for resolutions to be voted on at the AGM. The document is a formal notice and explanatory statement sent to shareholders to inform them about the upcoming AGM and the matters to be considered and voted upon. It does not contain the actual financial statements or reports themselves, nor is it a transcript or presentation. It is not a report publication announcement since it is substantive and lengthy (15,000 characters) and contains detailed meeting and voting information. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting, including notices and explanatory statements.
2017-04-06 English
Initial Director's Interest Notice 2 pages 115.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held or contracts noted. This is a standard form used to notify the market of a director's personal shareholdings or interests. It is not a financial report, audit, or management report, nor is it an announcement of voting results or capital changes. It fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions or interests by company directors and executives. The document length is short and focused solely on director interests, confirming this classification.
2017-04-02 English
CYC Board Changes 2 pages 365.5KB
Board/Management Information Classification · 100% confidence The document is an announcement from Cyclopharm Limited regarding changes in the company's board of directors, specifically the appointment of a new Chairman and an additional non-executive Director. It discusses governance and board expertise but does not contain financial statements, audit information, or detailed financial results. The content focuses on management and board changes rather than financial reporting or other regulatory filings. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5243 characters, which is sufficient for a detailed announcement but does not constitute a full report like an Annual Report or Interim Report.
2017-03-28 English
CYC Annual Report to Shareholders 110 pages 1.7MB
Annual Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Annual Report 2016' and contains detailed financial statements such as Statement of Comprehensive Income, Statement of Financial Position, Statement of Cash Flows, and Notes. It includes sections like Chairman's Letter, Managing Director's Review, Directors' Report, Auditor's Independence Declaration, Corporate Governance, and Independent Audit Report. The document covers the full fiscal year ending 31 December 2016 and provides comprehensive financial performance data, management commentary, and audited financial results. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. These characteristics align with the definition of an Annual Report (10-K). FY 2016
2017-03-27 English
CYC Appendix 4G 10 pages 84.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures required to be lodged with the ASX alongside the annual report. It includes detailed disclosures about the company's adherence to the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 31 December 2016. The document is a corporate governance statement or key to disclosures, not the full annual report itself. It is a regulatory filing required to accompany the annual report but does not contain full financial statements or comprehensive company activity details. The document is lengthy (15,000 characters) and contains substantive governance information, but it is not a financial report or earnings release. Therefore, the best classification is Regulatory Filings (RNS), as it is a compliance document related to governance disclosures under ASX rules, not the annual report or a governance report standalone.
2017-03-27 English
Becoming a substantial holder - AACCF (Amended) 3 pages 310.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of initial substantial holder under the Corporations Act 2001. It details the substantial shareholding of Anglo Australian Christian and Charitable Fund in Cyclopharm Limited, including voting power, relevant interests, registered holders, and consideration paid. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of shareholding. Therefore, the correct classification is MRQ with high confidence.
2017-03-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.